Research Article
Volume 9 Issue 3 - 2020
Standardized Sublingual Immunotherapy for Mites in Pediatric Patients, in a Six-Year Follow-Up Period, in a High Specialty Hospital in the City of Mexico
Sandra Guadalupe Bautista Garcia1*, Beatriz Bayardo Gutierrez1, Rolando Laurel Laurel1, Maria De Lourdes Patricia Ramirez Sandoval2 and Gerardo T Lopez Perez1
1National Institute of Pediatrics, Allergy Service, Mexico
2General Hospital of Zone Number 32 IMSS, Mexico
*Corresponding Author: Sandra Guadalupe Bautista Garcia, National Institute of Pediatrics, Allergy Service, Mexico.
Received: January 28,2020; Published: February 12, 2020


Introduction: Specific immunotherapy with allergens is the only treatment that can modify the natural course of allergic diseases. The dust mite is one of the most common aeroallergens in allergic rhinitis, allergic asthma and atopic dermatitis.

Justification: It is a therapy that is commonly administered to children because of its ease of application, and the adverse effects are less than with subcutaneous immunotherapy.

Objective: Describe the characteristics of patients aged 4 - 16 years who receive standardized sublingual immunotherapy against mites,

Method: Cross-sectional, observational, descriptive and retrospective study that includes patients diagnosed with allergic rhinitis, asthma and/or atopic dermatitis with positive skin tests exclusively for mites undergoing treatment with standardized sublingual immunotherapy for at least two years.

Statistical Analysis: With the study variables, the statistical program SPSS version 21 will be analyzed, with which the analysis will be carried out according to the type of variable and the results will be presented in tables and graph.

Results: The results of the case analysis are shown. of 63 patients, of these, it was found that 22 corresponded to female patients (34.9%). 100% of the patients had the diagnosis of allergic rhinitis; 74.5% also presented asthma and 6.3% of them also presented atopic dermatitis. No relationship was found between the size of the largest diameter of the papule measured in positive skin tests for mites. The average age of onset of sublingual immunotherapy to mites was 9.24 years, with an average treatment duration of 33.5 months. Immunotherapy effectiveness was reported in 88.9% of patients, 57.1% presented at some time assistance in the emergency department. 9.5% had adverse effects, the most common was local reaction in 7.9% and in 1.6% urticarial reaction.

Discussion: The prevalence of allergic diseases has increased considerably in the last 30 - 40 years. In our study, all cases presented allergic rhinitis; 74.5% also presented asthma and 6.3% of them also presented atopic dermatitis, 19% of the patients presented all three diseases. No relationship was found between the severity of allergic rhinitis with the size of the larger diameter of the papule versus each mite measured in skin tests.

Conclusion: Sublingual immunotherapy against mites is a specific treatment capable of controlling diseases such as allergic rhinitis, asthma and atopic dermatitis, as we find that it efficiently reduces both the symptoms, and the need for subjective pharmacological treatment, and that it is safe its administration

Keywords: Sublingual Immunotherapy; Rhinitis; Atopic Dermatitis; Asthma


  1. Saranz R., et al. “Inmunoterapia con alérgenos para la prevención y el tratamiento de las enfermedades alérgicas respiratorias de la infancia”. Archivos Argentinos de Pediatría 108 (2010): 258-265.
  2. Mesa M., et al. “Inmunoterapia específica con alérgenos en Pediatría”. Protocolos diagnósticos y terapéuticos en Pediatría 1 (2013): 145-156.
  3. De Castro G and Zicari A. “Efficacy of sublingual specific immunotherapy on allergic asthma and rhinitis in children's real life”. European Review for Medical and Pharmacological Sciences 17.17 (2013): 2225-22231.
  4. Francis S. “Atopic Dermatitis: Natural History, Diagnosis, and Treatment”. ISRN Allergy (2014): 1-7.
  5. Rodríguez O. “Inmunoterapia sublingual en rinitis alérgica y asma en niños de dos a cinco años sensibilizados con ácaros”. Revista de Alergia en México 55 (2008): 71-75.
  6. Ring J and Gutermuth J. “100 years of hyposensitization: history of allergen-specific immunotherapy (ASIT)”. Allergy 66 (2011): 713-724.
  7. Huerta J., et al. “Prevalencia y factores asociados de rinitis alérgica y dermatitis atópica en niños”. Alergia, Asma e Inmunología Pediátricas 17.2 (2008): 56-64.
  8. Ferrante G and La Grutta S. “The Burden of Pediatric Asthma”. Frontiers in Pediatrics 6 (2018): 1-7.
  9. Larenas., et al. “Guía Mexicana del Asma”. Neumología y Cirugía de Tórax (2017).
  10. Mancilla E., et al. “Prevalencia de rinitis alérgica y de sus síntomas en la población escolar de Cuernavaca, Morelos, México”. Revista Alergia México 6 (2017): 243-249.
  11. Sahin E, et al. “Mechanism of action of allergen immunotherapy”. American Journal of Rhinology and Allergy 30 (2016): 1-3.
  12. Jay D and Nadeau K. “Immune Mechanisms of Sublingual Immunotherapy”. Current Allergy Asthma Reports 14 (2014): 1-7.
  13. Bousquet J., et al. ARIA (Allergic Rhinitis and its Impact on Asthma) (2008). 
  14. Licari A, et al. “Difficult vs. Severe Asthma: Definition and limits of asthma control in the pediatric population”. Frontiers in Pediatrics 19.6 (2018): 1-11.
  15. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention (2018).
  16. Glenis K. “Optimal management of allergic rhinitis”. Archives of Disease in Childhood 100 (2015): 576-578.
  17. Tourlas K and Burman D. “Allergy Testing”. Primary Care Clinics in Office Practice 43 (2016): 363-374.
  18. Nanette B. “Typical and atypical clinical appearance of atopic dermatitis”. Clinics in Dermatology 35 (2017): 354-359.
  19. Boguniewicz M., et al. “Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape”. Annals of Allergy and Immunology 120 (2018): 10-22.
  20. Park K. “Sensitization to various minor house dust mite allergens is greater in patients with atopic dermatitis than in those with respiratory allergic disease”. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 48 (2018): 1050-1058.
  21. Calderón M. “Respiratory allergy caused by house dust mites: What do we really know?”. Journal of Allergy and Clinical Immunology 136 (2015): 38-48.
  22. Rodríguez O. “Eficacia y seguridad de la inmunoterapia sublingual en niños menores de dos años con rinitis y asma bronquial sensibilizados a los ácaros domésticos”. Alergia, Asma e Inmunología Pediátricas 24 (2015): 12-17.
  23. Rodríguez O. “Inmunoterapia con extractos industriales de ácaros domésticos en niños menores de 5 años con rinitis y asma”. VacciMonitor 27 (2018): 61.66.
  24. Bernstein D., et al. “A practical guide to the sublingual immunotherapy tablet adverse event profile: implications for clinical practice”. Postgraduate Medicine (2017).
  25. Ciprandi G., et al. “Sublingual immunotherapy in children with allergic polysensitization”. Allergy and Asthma Proceedings 3 (2010): 227-231.
  26. Poddighe D., et al. “Sublingual immunotherapy for pediatric allergic rhinitis: The clinical evidence”. World Journal of Clinical Pediatrics 8 (2016): 47-56.
  27. Slavyanakaya T., et al. “Debates in allergy medicine: specific immunotherapy efficiency in children with atopic dermatitis”. World Allergy Organizational Journal 9 (2016): 1-11.
  28. Santos da Silva E., et al. “Allergens of Blomia tropicalis: An Overview of recombinant molecules”. International Archives of Allergy and Immunology 172 (2017): 203-214.
  29. Sitio web oficial del Instituto Nacional de Estadística y Geografía (INEGI).
  30. Ahanchian H., et al. “Evaluation of Clinical and Laboratory Data in Patients with Recurrent Infections and Suspected Immunodeficiency”. International Journal of Pediatrics 2 (2014): 19-24.
  31. Giovanni B., et al. “Safety of Sublingual Immunotherapy in Children with Asthma”. Pediatric Drugs 5 (2003): 777-781.
Citation: Sandra Guadalupe Bautista Garcia., et al. “Standardized Sublingual Immunotherapy for Mites in Pediatric Patients, in a Six-Year Follow-Up Period, in a High Specialty Hospital in the City of Mexico”. EC Paediatrics 9.3 (2020): 01-10.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

December Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the November issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before December 23, 2022.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.